Cheng, Lauren Y.
Haydu, Lauren E.
Song, Ping
Nie, Jianyi
Tetzlaff, Michael T.
Kwong, Lawrence N.
Gershenwald, Jeffrey E.
Davies, Michael A.
Zhang, David Yu
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (P50 CA093459)
U.S. Army Medical Research Acquisition Activity (W81XWH1810144)
National Institutes of Health (R01CA203964)
Cancer Prevention and Research Institute of Texas (RP180147)
Article History
Received: 16 November 2020
Accepted: 8 April 2021
First Online: 27 April 2021
Competing interests
: LYC, PS, and JN consult for NuProbe USA. MTT has advisory board relationships with Novartis, LLC, Myriad Genetics, and Nanostring. LNK reports receiving a commercial research grant from Array Biopharma. JEG has served as a consultant and/or on an advisory board for Merck, Syndax, Novartis, and Bristol Myers Squibb (unrelated to the content of this work). Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI 2T32CA009666-21, Cancer Fighters of Houston, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. MAD has been a consultant to Roche/Genentech, Array, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex and Apexigen, and he has been the PI of funded research grants to his institution by Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, and Oncothyreon, and is supported by the Dr. Miriam and DYZ is a co-founder, significant equity holder, and consultant of NuProbe Global and of Torus Biosystems, and is a consultant for Avenge Bio. LEH reports no conflict of interest.